In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
|Articles|November 6, 2019
Using IPL to treat glaucoma patients with dry eye disease
Author(s)Alex Delaney-Gesing
Advertisement
Steven Vold, MD, founder and CEO of
See more content from AAO 2019.
Advertisement
Related to this article
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.
Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves subcutaneous Enspryng for TED
2
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
3
OT Roundup: Optogenetics Nobel Prize, BRUNELLO, DRAGON, eye transplant
4
Introducing Noah Banoub: The medical student’s path from church pews to the retina clinic
5